1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Global Cancer Therapies Industry

Global Cancer Therapies Industry

  • October 2011
  • -
  • Global Industry Analysts

Summary

Table of Contents

This report analyzes the worldwide markets for Cancer Therapies in US$ Million by the following Product Segments: Immunotherapy, Targeted Therapy, Hormonal Therapy, and Chemotherapy. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. A six-year historic analysis is also provided for these markets. The report profiles 152 companies including many key and niche players such as Amgen, Inc., AstraZeneca PLC, Bayer Schering Pharma, Biogen Idec Inc., Bristol-Myers Squibb Company, Celgene Corporation, Cell Therapeutics, Inc., Cephalon, Inc., Chugai Pharmaceutical Co., Ltd., Eli Lilly and Company, Imclone Systems, Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., Genzyme, GlaxoSmithKline, Janssen Biotech, Inc., Merck KGaA, Novartis AG, OSI Pharmaceuticals, Inc., Pfizer, Sanofi-Aventis, Seattle Genetics, Inc., and Takeda Pharmaceutical Company Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

Get This Report

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Non-Small Cell Lung Cancer: KOL Insight

Non-Small Cell Lung Cancer: KOL Insight

  • $ 7 495
  • Industry report
  • July 2015
  • by Firstword Pharma

Non-Small Cell Lung Cancer: KOL Insight offers detailed expert opinion on the continuing evolution of the treatment paradigm for EGFR/ALK positive and negative NSCLC, and the potential for targeting ...

Idiopathic Pulmonary Fibrosis: KOL Insight

Idiopathic Pulmonary Fibrosis: KOL Insight

  • $ 7 495
  • Industry report
  • May 2015
  • by Firstword Pharma

Roche’s Esbriet, (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib) are the only approved therapies for Idiopathic Pulmonary Fibrosis (IPF). Will either be able to establish themselves as ...

Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy - Identifying and Commercializing First-in-Class Innovation

  • $ 6 995
  • Industry report
  • May 2015
  • by GBI Research

Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy - Identifying and Commercializing First-in-Class Innovation Summary Highly Innovative and Diverse Pipeline The Duchenne Muscula ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.